Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Running, not enrolling · Early Phase 1

Conditions studied: Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma

In brief

LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).

Key facts

Study ID

NCT04134325

Run by

UNC Lineberger Comprehensive Cancer Center

People needed

10

Starts

2019-09-01

Expected to finish

2037-07-07

Last updated by the study team

2026-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Lineberger Comprehensive Cancer Center at University of North Carolina — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.